Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 5—May 2015
Research

Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013

Stéphane JauréguiberryComments to Author , Marc Thellier, Papa Alioune Ndour, Flavie Ader, Camille Roussel, Romain Sonneville, Julien Mayaux, Sophie Matheron, Adela Angoulvant, Benjamin Wyplosz, Christophe Rapp, Thierry Pistone, Bénédicte Lebrun-Vignes, Eric Kendjo, Martin Danis, Sandrine Houzé, François Bricaire, Dominique Mazier, Pierre Buffet, Eric Caumes, and French Artesunate Working Group
Author affiliations: Université Pierre et Marie Curie, Paris, France (S. Jauréguiberry, M. Thellier, P.A. Ndour, C. Roussel, M. Danis, D. Mazier, P. Buffet, E. Caumes); Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (APHP), Paris (S. Jauréguiberry, M. Thellier, F. Ader, J. Mayaux, B. Lebrun-Vignes, M. Danis, F. Bricaire, D. Mazier, P. Buffet, E. Caumes); Centre National de Référence du Paludisme, Paris (S. Jauréguiberry, M. Thellier, E. Kendjo, M. Danis, D. Mazier, P. Buffet); Hôpital Bichat, APHP, Paris (R. Sonneville, S. Matheron, S. Houzé); Université Paris-Sud, Orsay, France (A. Angoulvant); Hôpital de Bicêtre, Le Kremlin Bicêtre, APHP, France (A. Angoulvant, B. Wyplosz); Hôpital d’Instruction des Armées Begin, St. Mandé, France (C. Rapp); Hôpital Pellegrin, Bordeaux, France (T. Pistone)

Main Article

Table 1

Severity of reported adverse events possibly associated with artesunate treatment of severe imported malaria in 117 patients, France, 2011–2013*

Adverse event
 Grade 1, mildly severe
 Grade 2, moderately severe
 Grade 3, severe
 Grade 4, life threatening
Total
Cutaneous 2† 1‡ 0 0 3
Ataxia, tremor, CNS ischemia 0 2 1 1 4
Tinnitus 1 0 0 0 1
Cardiac and arterial ischemia 1 1 1 1 4
Hypertension 0 0 1§ 0 1
Elevated level of ALT 2 2 3 1 8
Hyperkalemia 1 0 0 0 1
Anemia¶ 20 11 27 17 75
Total 27 17 33 20 97

*Adverse events were obtained from medical charts and graded by using the National Institutes of Health classification for side effects (http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf). ALT, alanine transaminase; CNS, central nervous system.
†Mild pruritus and rash.
‡Telogen effluvium.
§Regressive retinopathy.
¶Grading was done during the follow-up by using available nadir of hemoglobin. For HIV-negative patients, the severity of anemia was graded as follows: grade 1, 10.0–10.9 g/dL; grade 2, 9.0–9.9 g/dL; grade 3, 7.0–8.9 g/dL, grade 4, <7.0 g/dL. For HIV-positive patients, the severity of anemia was graded as follows: grade 1, 8.5–10.0 g/dL; grade 2.0, 7.5–8.4 g/dL; grade 3, 6.5–7.4 g/dL; grade 4, <6.5 g/dL.

Main Article

1Members of the French Artesunate Working Group are listed in the Technical Appendix.

Page created: April 17, 2015
Page updated: April 17, 2015
Page reviewed: April 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external